In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
What you're asking when you think about maternal mortality and the crises that we're experiencing right now, it really does go beyond a single individual, person being impacted. What I mean by this is that poor outcomes of an individual person can really have disastrous social and economic effects, not only on that woman, but her family and the communities around her. For example, if you think about birth complications for that mom, it can lead to a substantial health expense for the acute care timeframe, but also potentially long term, including potentially the need for blood transfusions, significant morbidity, and mortality for the child.
Also, when you think about this, we also have to realize that some of these complications don't have a short term. They can actually last longer. And so long term care can lead to a reduction in one's ability to participate in the workforce and additional economic and productivity losses, again, not only for that individual family, but for society as a whole. And then there's a possibility to have physical and emotional impact that can last for a long time, it's really important to recognize that what we're talking about is not just about the impact to an individual woman through a very narrow definition, but it's about how this impacts our economy and our society as a whole.
The facts are really clear, investing in the health of a woman is important for not only that individual, but entire communities, including men, women, and children. And if we're thinking about this ripple effect, we need to really mobilize to achieve better health outcomes and turn a greater eye towards the needs of women everywhere. Now how, how this can also manifest itself is with the realities that we face today when we think about how many women, far too many women, are experiencing morbidity and mortality at really alarming rates, and it's partially in due to a lack of access to the necessary maternal health care services that are needed.
This is what we call maternity care deserts, which are counties where you don't have a hospital or a birth center that offer obstetrical care. In 2024 we can still talk about this, which is very sad when you look at the March of Dimes data, nearly 35% of all US counties are considered deserts. This affects nearly 2.2 million women and 150,000 babies. Then when you think about the next layer, where you have limited maternity care, there's another 4.7 million women who are affected there. When you think about these barriers for women as a whole, it's even greater for underrepresented communities. Black women in the US are more than three times likely to die from a pregnancy related condition compared to white women, according to the CDC. So as a whole, the impact to our society is substantial. And this is what I think we have to really think about, is not only the impact to the individual mom and her family, but to society as a whole.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.